Acrylanz

Acrylanz (international name Lansoprazole) is a drug belonging to the group of antiulcer drugs. It is used to treat various gastrointestinal diseases such as gastric and duodenal ulcers, reflux esophagitis, non-ulcer dyspepsia, Zollinger-Ellison syndrome, erosive-ulcerative esophagitis and Helicobacter pylori infection.

Manufacturers of Akrilanza are Akrikhin HFC (Russia). The dosage form of Acrilanza is capsules with a dosage of 30 mg. The active substance is lansoprazole.

In addition to the main indications for use, the drug can be used to treat benign gastric ulcers and Helicobacter pylori infection in combination with other medications. However, Acrilanz has a number of contraindications, including hypersensitivity to the drug, malignant neoplasms of the gastrointestinal tract, pregnancy and lactation. Also, there are restrictions for use in patients with impaired liver function, in old age and under 18 years of age.

Some side effects that may occur while using Acrilanza include headache, dizziness, depression, nausea, diarrhea, abdominal pain, loss of appetite, increased liver enzymes, and many others.

The drug may also interact with other drugs, including antacids containing algeldrate and magnesium hydroxide, ampicillin, digoxin, ketoconazole, cyanocobalamin, iron salts and others.

In case of overdose, symptomatic therapy is recommended, and hemodialysis is ineffective. Before starting and after finishing therapy, endoscopic monitoring is required to exclude malignant neoplasms.

In general, Acrilanz is an effective drug for the treatment of various diseases of the gastrointestinal tract. However, its use should only occur under medical supervision and in accordance with the instructions for use.